DeepMed Research

Mirum Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2018-01-01

Employees: 264

Market Cap: $2.1B

Website: http://www.mirumpharma.com

Introduction: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Clinical Trials

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Phase 3

Recruiting

Conditions: Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

Interventions: Other: Placebo
Drug: Maralixibat

First Posted Date: 2024-08-14

Last Posted Date: 2025-05-01

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT06553768

Locations: 🇺🇸
Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
🇺🇸
Stanford Children's Health in Palo Alto, Palo Alto, California, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States

and more 29 locations

Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)

Recruiting

Conditions: Alagille Syndrome

Interventions: Drug: Maralixibat

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-27

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT06193928

Locations: 🇺🇸
Children's Hospital Los Angeles CHLA, Los Angeles, California, United States
🇺🇸
Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado, Aurora, Colorado, United States
🇺🇸
Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta, Georgia, United States

and more 5 locations

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Phase 2

Recruiting

Conditions: Primary Biliary Cholangitis
PBC

Interventions: Drug: Volixibat
Drug: Placebo

First Posted Date: 2021-09-20

Last Posted Date: 2025-05-16

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 180

Registration Number: NCT05050136

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 88 locations

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Phase 2

Completed

Conditions: Alagille Syndrome
Progressive Familial Intrahepatic Cholestasis
Cholestatic Liver Disease

Interventions: Drug: Maralixibat

First Posted Date: 2021-01-28

Last Posted Date: 2025-02-06

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 27

Registration Number: NCT04729751

Locations: 🇵🇱
Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw, Poland
🇬🇧
King's College Hospital, London, United Kingdom
🇺🇸
University of California - San Francisco, San Francisco, California, United States

and more 11 locations

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Phase 2

Terminated

Conditions: Intrahepatic Cholestasis of Pregnancy

Interventions: Drug: Volixibat
Drug: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2024-08-06

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 4

Registration Number: NCT04718961

Locations: 🇺🇸
The University of Texas Medical Branch - Galveston, Galveston, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 17 locations

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Phase 2

Recruiting

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Volixibat
Drug: Placebo

First Posted Date: 2020-12-11

Last Posted Date: 2025-05-23

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 200

Registration Number: NCT04663308

Locations: 🇨🇦
McMaster University Hospital, Hamilton, Ontario, Canada
🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

and more 100 locations

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Conditions: Alagille Syndrome

First Posted Date: 2020-08-28

Last Posted Date: 2021-10-20

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Registration Number: NCT04530994

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 11 locations

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Phase 2

Completed

Conditions: Biliary Atresia

Interventions: Drug: Maralixibat
Other: Placebo

First Posted Date: 2020-08-24

Last Posted Date: 2025-03-19

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 75

Registration Number: NCT04524390

Locations: 🇻🇳
Vietnam National Children's Hospital, Hanoi, Vietnam
🇨🇳
Children's Hospital of Fudan University, Shanghai, China
🇨🇳
The Children's Hospital, Zhejiang University School of Medicine, Hanzhou, Zhejiang, China

and more 19 locations

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Phase 3

Completed

Conditions: CTX

Interventions: Drug: CDCA Weight-Based Dose TID
Drug: Blinded CDCA 250 mg TID
Drug: Placebo
Drug: Open-Label CDCA 250 mg TID
Drug: Rescue Medication CDCA 250 mg TID

First Posted Date: 2020-02-17

Last Posted Date: 2024-10-28

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 19

Registration Number: NCT04270682

Locations: 🇧🇷
Travere Investigational Site, São Paulo, SP, Brazil

An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase 3

Active, not recruiting

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)

Interventions: Drug: Maralixibat

First Posted Date: 2019-12-04

Last Posted Date: 2025-02-14

Lead Sponsor: Mirum Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT04185363

Locations: 🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Medstar Georgetown University Hospital, Washington, District of Columbia, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy